PD-L1 expression ≥ 1%

1 drugs

Predictive biomarker for patient selection in 6 indications

Approved Drugs

Indications

Companies

PD-L1 expression ≥ 1% is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 6 indications including Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma. Explore the targeted therapies, indications, testing methods, and companies developing PD-L1 expression ≥ 1% drugs below.

Search PD-L1 expression ≥ 1% Clinical Trials

Search recruiting trials on ClinicalTrials.gov

Drugs Targeting PD-L1 expression ≥ 1%

Drug	Company	Therapeutic Area
TECENTRIQ HYBREZA	Roche	Oncology

PD-L1 expression ≥ 1% Indications

Non-Small Cell Lung Cancer Small Cell Lung Cancer Hepatocellular Carcinoma Melanoma Alveolar Soft Part Sarcoma Muscle Invasive Bladder Cancer

Companies with PD-L1 expression ≥ 1% Drugs

Roche